SAM #36C24426Q0669

Radiopharmaceuticals Supply IDIQ for VA Pittsburgh Healthcare System

This opportunity is for a 5-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract to supply radiopharmaceuticals to the VA Pittsburgh Healthcare System's Nuclear Medicine Department. - Government Buyer: - Department of Veterans Affairs, Network Contracting Office 4, Services 5, Wilkes-Barre PA - Products Requested: - 31 radiopharmaceutical line items, including: - UltraTag Kits (200 units) - PYP cold vials (325 units) - PYP hot unit dose (325 units) - Ga-67 unit dose (75 units) - I-123 100 Microcurie Caps (1500 units) - I-123 Whole Body Caps (5mCi) (250 units) - I-123 MIBG unit dose (25 units) - Tc-MAA unit dose (500 units) - Tc-MDP unit dose (1750 units) - Tc-Mag 3 unit dose (250 units) - Tc-Flood source (1750 units) - Tc-Bulk Linearity (40 units) - Tc-DTPA aerosol unit dose (500 units) - Tc-DTPA renal unit dose (200 units) - Tc-DMSA unit dose (50 units) - Tc-Sestamibi unit dose (300 units) - Tc-Myoview unit dose (20,000 units) - Tc-Sulfur Colloid unit dose (900 units) - Tc-Sulfur Colloid filtered unit dose (250 units) - Sincalide vials (150 units) - ACD Solution vials (150 units) - I-131 diagnostic caps (100 units) - Tl-201 unit dose (200 units) - In-111 WBC procedure (400 units) - Tc-Ceretec WBC procedure (40 units) - In-111 Octreotide unit dose (25 units) - I-131 treatment first millicurie (400 units) - Tc-Mebrofenin unit dose (650 units) - Technetium injection unit dose (300 units) - I-131 treatment additional millicurie (20,000 units) - Tc-HDP unit dose (650 units) - Unique Requirements: - Compliance with NRC, FDA, DOT, and other regulatory standards - Emergency and after-hours delivery capabilities - Annual ordering periods with firm-fixed priced task orders - OEMs: - No specific OEMs are named in the solicitation; typical manufacturers for these products include Cardinal Health, GE Healthcare, and Lantheus Medical Imaging - Vendors: - No specific vendors are named; opportunity is open to qualified suppliers of radiopharmaceuticals - Estimated contract value: - Based on scope and quantities, likely in the multi-million dollar range over five years - Period of Performance: - August 15, 2026 – August 14, 2031 (5 years) - Annual ordering periods

Description

21231

View original listing